|
August 1, 2010 - Covering drugs, devices, and diagnostics for the brain and nervous system
|
|
| Subscribe for
full access to Neurotech Insights |
Subscription includes monthly pdf delivery of full newsletter and access to searchable web archive with over 2000 CNS stories
$1450 - Individual
$2450 - Team |
| CNS Market Report |
6th Annual
Updated and Expanded
500 pages
'A must read for every executive in CNS'
|
|
|
This month, M&A activity in the neurovascular arena continued to heat up with Johnson and Johnson declaring its intent to purchase Micrus Endovascular for $480 million. On the heals of the acquisition of BioLineRx's antipsychotic, Cypress Bioscience is facing a hostile buyout offer from one of its largest investors. An FDA panel voted against approval of Vivus' Qnexa for obesity. What does it mean for Arena and Orexigen (more)? |
Product and Clinical Trial Updates
|
|
- Xenoport dives on migraine trial failure >>>
- NeuroPace submits PMA for responsive neurostimulation >>>
- VisionCare eye prosthetic approved for AMD >>>
- FDA panel snubs Vivus' Qnexa due to safety concerns >>>
26 more product development stories in this issue of Neurotech Insights >>> |
Company Spotlight
|
|
 Interview with to-BBB CEO Willem van Weperen
We talked with the CEO of to-BBB Willem van Weperen about how the company is leveraging a new platform for blood brain barrier delivery to advance a treatment for brain tumors as well as R&D partnerships with pharma and biotech. >>> |
| Deals, Alliances and Financings |
|
- Eisai acquires North American rights to Arena's locaserin >>>
- EndoStim raises $6 million for GERD neurostimulation >>>
- Actelion buys option to acquire ALS company Trophos >>>
- Euthymics gets $24 million to cull Dov assets >>>
13 more financing stories in this issue of Neurotech Insights >>> |
| Featured Topic - The BBB: Who Will Deliver? |
|
| This month's feature article discusses local and global methods for delivering drugs across the blood brain barrier including devices, conjugates, cells, gene therapy, liposomes, and nanoparticles. Companies covered include Amgen, AngioChem, Armagen, Biovail, BrainsGate, Capsulution, CellMed, Ceregene, Eisai, Inset, MedGenesis, Medtronic, Nanovector, Neurotech SA, NsGene, Neurologix, Palyon, St. Jude, Stem Cell Therapeutics, to-BBB, Xigen >>>
|
| NIH Corner: Collaboration Made Simple |
|
Have you ever come across NIH research or met an investigator that your company could benefit from working with? This article provides an insider's guide to the collaboration mechanisms and opportunities for working with NIH. >>>
|
| Highlights from ICAD 2010 - Honolulu, HI |
|
| New Studies Shed Light on Interplay of Alzheimer's Proteins >>> |
| NASDAQ NeuroInsights Neurotech Index |
|
As of July 31 2010, ^NERV is down 16.0% from a start date of Sept. 25, 2007, compared to a loss of 2.1% in the NASDAQ Biotech Index and loss of 27.8% for the S&P 500.
|
|
|
|
|
|
|
|
|
NeuroInsights | 30th St | San Francisco | CA | 94131 |
|
|
